Novel approaches to the treatment of hyperhomocysteinaemia

Bibliography

• CARSON NAJ, DENT CE, FIELD CMB, GAULL GE: Homocystinuria: clinical and pathological review of ten cases. J. Ped. (1965) 66(3):565–583.
   PubMed Web of Science ®Google Scholar
• MCCULLY KS: Vascular pathology of homocysteinemia. Implications for the pathogenesis of arteriosclerosis. Am. J. Pathology (Phila.) (1969) 56:111–128.
   Google Scholar
• BOERS GH, SMALS AG, TRIJBELS FJ et al: Heterozygosity for homocystinuria in premature peripheral and cerebral occlusive arterial disease. N Engl..). Med. (1985) 313(12)709–715.
   Google Scholar
• KLUIJTMANS LA, VAN DEN HEUVEL LE BOERS GH et al: Molecular genetic analysis in mild hyperhomocysteinemia: a common mutation in the methylenetetrahydrofolate reductase gene is a genetic risk factor for cardiovascular disease. Am. J. Hum. Genet. (1996) 58(1):35–41.
   PubMed Web of Science ®Google Scholar
• WALD NJ, WATT HC, LAW MR, WEIR DG, MCPARTLIN J, SCOTT JM: Homocysteine and ischemic heart disease. Arch. Intern. Med. (1998) 158:862–867.
   PubMed Web of Science ®Google Scholar
• DALERY K, LUSSIER-CACAN S, SELHUB J, DAVIGNONJ, LATOUR Y, GENEST J Jr: Homocysteiene and coronary artery disease in French Canadian subjects: relation with vitamins B12, B6, pyridoxal phosphate, and folate. Arn. Cardiol (1995) 75:1107–1111.
   PubMed Web of Science ®Google Scholar
• SELHUB J, JACQUES PF, BOSTOM AG et al.: Association between plasma homocysteine concentrations and extracranial carotid-artery stenosis. N Engl. J Med. (1995) 332:286–291.
   PubMed Web of Science ®Google Scholar
• STAMPFER MJ, MALINOW MR, WILLETT WC et al.: A prospective study of plasma homocysteine and risk of myocardial infarction in US physicians. JAMA (1992) 268(7):877–881.
   PubMed Web of Science ®Google Scholar
• BOUSHEY CJ, BERESFORD SAA, OMENN GS, MOTULSKY AG: A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. JAMA (1995) 274:1049–1057.
   PubMed Web of Science ®Google Scholar
• CLARKE R, DALY L, ROBINSON K et al: Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl. J. Med. (1991) 324:1149–1155.
   PubMed Web of Science ®Google Scholar
• DEN HEIJER M, KOSTER T, BLOM HJ et al: Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. N Engl. J. Med. (1996) 334:759–762.
   PubMed Web of Science ®Google Scholar
• MANDEL H, BRENNER B, BERANT M et al.: Coexistence of hereditary homocystinuria and Factor V leiden - effect on thrombosis. N Engl. J. Med. (1996) 334:763–768.
   PubMed Web of Science ®Google Scholar
• GRAHAM IM, DALY LE, REFSUM HM et al: Plasma homocysteine as a risk factor for vascular disease. JAMA (1997) 277:1775–1781.
   PubMed Web of Science ®Google Scholar
• FOLSOM AR, NIETO J, MCGOVERN PG et al.: Prospective study of coronary heart disease incidence in relation to fasting total homocysteine, related genetic polymorphisms, and B vitamins. The atherosclerosis risk in communities (ARIC) study. Circulation (1998) 98:204–210.
   PubMed Web of Science ®Google Scholar
• EVANS, RW, SHATEN BJ, HEMPEL JD, CUTLER JA, KULLER LH: Homocysteine and risk of cardiovascular disease in the multiple risk factor intervention trial. Arteriosder. Thromb. Vasc. Biol. (1997) 17:1947–1953.
   PubMed Web of Science ®Google Scholar
• SCHORAH CJ, DEVITT H, LUCOCK M, DOWELL AC: The responsiveness of plasma homocysteine to small increases in dietary folic acid: a primary care study. Eur. I Cilia. Num. (1998) 52:407–411.
   PubMed Web of Science ®Google Scholar
• MALINOW MR, DUELL PB, HESS DL et al.: Reduction of plasma homocysteine levels by breakfast cereal fortified with folic acid in patients with coronary heart disease. N. Engl. J. Med. (1998) 338:1009–1015.
   PubMed Web of Science ®Google Scholar
• VENN BJ, MANN JI, WILLIAMS SM et al: Dietary counseling to increase natural folate intake: a randomized, placebo-controlled trial in free-living subjects to assess effects on serum folate and plasma total homocysteine. Am. J. Cita Nuo: (2002) 76:758–765.
   PubMed Web of Science ®Google Scholar
• RIDDELL LJ, CHISHOLM A, WILLIAMS S, MANN JI: Dietary strategies for lowering homocysteine concentrations. Am.j Clin. Num. (2000) 71:1448–1454.
   PubMed Web of Science ®Google Scholar
• TICE JA, ROSS E, COXSON PG et al: Cost-effectiveness of vitamin therapy to lower plasma homocysteine levels for the prevention of coronary heart disease: effect of grain fortification and beyond. JAMA (2001) 286(8):936–943.
   PubMed Web of Science ®Google Scholar
• HOMOCYSTEINE LOWERING TRIALISTS' COLLABORATION: Lowering blood homocysteine with folic acid based supplements: meta-analysis of randomized trials. BMI (1998) 316:894–898.
   PubMedGoogle Scholar
• MALINOW MR, NIETO FJ, KRUGERWD et al: The effects of folic acid supplements on plasma total homocysteine are modulated by multivitamin use and methylenetetrahydrofolate reductase genotypes. Arteriosder Thromb. Vasc. Biol. (1997) 17:1157–1162.
   PubMed Web of Science ®Google Scholar
• WOO KS, CHOOK P, CHAN LLT et al:Long-term improvement in homocysteine levels and arterial endothelial function after 1-year folic acid supplementation. Am. J. Med. (2002) 112(7):535–539.
   PubMed Web of Science ®Google Scholar
• VAN DER GRIEND R, BIESMA DH, HAAS FJLM et al.: The effect of different treatment regimens in reducing fasting and postmethionine-load homocysteine concentrations. Int. Med. (2000) 248:223–229.
   Google Scholar
• FOHR IP, PRINZ-LANGENOHL R, BRONSTROP A et al: 5,10-Methylenetetrahydrofolate reductase genotype determines the plasma-homocysteine-lowering effect of supplementation with 5-methylenetetrahyrofolate or folic acid in healthy young women. Am. j. Chit. Nutr. (2002) 75:275–282.
   PubMed Web of Science ®Google Scholar
• GUTTORMSEN AB, UELAND PM, NESTHUS I et al.: Determinants and vitamin responsiveness of intermediate hyperhomocysteinemia (40 pmo1/0. The Hordaland homocysteine study. Chit. Invest. (1996) 98:2174–2183.
   PubMed Web of Science ®Google Scholar
• FRANKEN DG, BOERS GH, BLOM HJ, TRIJBELS FJ, KLOPPENBORG PW: Treatment of mild hyperhomocysteinemia in vascular disease patients. Arteriosclec Thromb. (1994) 14:465–470.
   PubMed Web of Science ®Google Scholar
• UBBINK JB, VAN DER MERWE A, DELPORT R et al.: The effect of a subnormal vitamin B6 status on homocysteine metabolism. Clin. Invest. (1996) 98:177–184.
   Google Scholar
• UBBINKJB, VERMAAK WJH, VAN DER MERWE A, BECKER PJ, DELPORT R, POTGIETER HC: Vitamin requirements for the treatment of hyperhomocysteinemia in humans. J. Nutr. (1994) 124:1927–1933.
   PubMed Web of Science ®Google Scholar
• BRATTSTROM L, ISRAELSSON B, NORRVING B et al.: Impaired homocysteine metabolism in early-onset cerebral and peripheral occlusive arterial disease. Atherosclerosis (1990) 81:51–60.
   PubMed Web of Science ®Google Scholar
• VAN DEN BERG M, FRANKEN DG, BOERS GHJ et al.: Combined vitamin B6 plus folic acid therapy in young patients with arteriosclerosis and hyperhomocysteinemia. Vasc. Surg. (1994) 20:933–940.
   Google Scholar
• DUDMAN NP, WILCKEN DE, WANG J, LYNCH JF, MACEY D, LUNDBERG P: Disordered methionine/homocysteine metabolism in premature vascular disease. Its occurrence, cofactor therapy, and enzymology. Arterioscler: Thromb. (1993) 13:1253–1260.
   PubMedGoogle Scholar
• SIMOLIN LA, BENEVENGA NJ, BERLOW S: The use of betaine for the treatment of homocystinuria. Pediatr. (1981) 99:467–472.
   Web of Science ®Google Scholar
• WILCKEN DE, WILCKEN B, DUDMAN P, TYRRELL PA: Homocystinuria - the effect of betaine in the treatment of patients not responsive to pyridoxine. N Engl. .1 Med. (1983) 309:448–453.
   Google Scholar
• BALIGA BS, REYNOLDS T, FINK LM, FONSECA VA: Hyperhomocysteinemia in Type 2 diabetes mellitus: cardiovascular risk factors and effect of treatment with folic acid and pyridoxine. Endocr: Pract. (2000) 6(6):435–441.
   PubMedGoogle Scholar
• BOSTOM AG, COLLETON BF: Hyperhomocysteinemia in chronic renal disease. J. Am. Soc. Nephrol. (1999) 10:891–900.
   PubMed Web of Science ®Google Scholar
• VAN GULDENER C, JANSSEN MJFM, DE MEER K, DONKER AJM, STEHOUWER CDA: Effect of folic acid and betaine on fasting and postmethionine-loading plasma homocysteine and methionine levels in chronic haemodialysis patients. Int. Med. (1999) 245:175–183.
   Web of Science ®Google Scholar
• VAN GULDENER C, JANSSEN MJ, LAMBERT J et al: No change in impaired endothelial function after long-term folic acid therapy of hyperhomocysteinaemia in haemodialysis patients. Nephr: Dialysis Transpl. (1998) 13(1):106–112.
   PubMed Web of Science ®Google Scholar
• BOSTOM AG, SHEMIN D, LAPANE KL et al.: High dose-B-vitamin treatment of hyperhomocysteinemia in dialysis patients. Kidney Int. (1996) 49(1):147–152.
   PubMed Web of Science ®Google Scholar
• BILLIONS, TRIBOUT B, CADET E et al:Hyperhomocysteinaemia, folate and vitamin B12 in unsupplemented haemodialysis patients: effect of oral therapy with folic acid and vitamin B12. Nephrol. Dial. Transplant. (2002) 17:455–461.
   PubMedGoogle Scholar
• TREMBLAY R, BONNARDEAUX A, GEADAH D et al.: Hyperhomocysteinemia in hemodialysis patients: effects of 12-month supplementation with hydrosoluble vitamins. Kidney Int. (2000) 58:851–858.
   PubMed Web of Science ®Google Scholar
• SUNDER-PLASSMANN G, FODINGER M, BUCHMAYER H et al: Effect of high-dose folic acid therapy on hyperhomocysteinemia in hemodialysis patients: results from the Vienna Multicenter Study. J. Am. Soc. Nephrol. (2000) 11:1106–1116.
   PubMed Web of Science ®Google Scholar
• MANNS B, HYNDMAN E, BURGESS E et al.: Oral vitamin B12 and high-dose folic acid in hemodialysis patients with hyper-homocyst(e)inemia. Kidney Int. (2001) 59:1103–1109.
   PubMed Web of Science ®Google Scholar
• TOUAM M, ZINGRAFFJ, JUNGERS P, CHADEFAUX-VEKEMANS B, DROEKE T, MASSY ZA: Effective correction of hyperhomocysteinemia in hemodialysis patients by intravenous folinic acid and pyridoxine therapy. Kidney Int. (1999) 56:2292–2296.
   PubMed Web of Science ®Google Scholar
• BOSTOM AG, SHEMIN D, GOHH RY et al.: Treatment of hyperhomocysteinemia in hemodialysis patients and renal transplant recipients. Kidney Int. (2001) 59(S78):S246–S252.
   Google Scholar
• BOSTOM AG, SHEMIN D, BAGLEY P et al.: Controlled comparison of L-5-methyltetrahydrofolate versus folic acid for the treatment of hyperhomocysteinemia in hemodialysis patients. Circulation (2000) 101:2829–2832.
   PubMed Web of Science ®Google Scholar
• BOSTOM AG, SHEMIN D, GOHH RY et al.: Treatment of mild hyperhomocysteinemia in renal transplant recipients versus hemodialysis patients. Transplantation (2000) 69:2128–2131.
   PubMedGoogle Scholar
• BEAULIEU AJ, GOHH RY, HAN H, HAKAS D et al: Enhanced reduction of fasting total homocysteine levels with supraphysiological versus standard multivitamin dose folic acid supplementation in renal transplant recipients. Arterioscler: Thromb. Vasc. Biol. (1999) 19(12):2918–2921.
   PubMed Web of Science ®Google Scholar
• ZANTVOORT FA, WALDMANN J, COLIC D, LISON AE: Incidence and treatment of hyperhomocysteinemia after renal transplantation. Transpl. Proc. (2001) 33:3679–3680.
   PubMed Web of Science ®Google Scholar
• ARNESEN E, REFSUM H, BONAA KH, UELAND PM, FORDE OH, NORDREHAUG JE: Serum total homocysteine and coronary heart disease. Int. J. Epid. (1995) 24:704–709.
   PubMed Web of Science ®Google Scholar
• VERHOEF P, KOK FJ, KRUYSSEN DACM et al: Plasma total homocysteine, B vitamins, and risk of coronary atherosclerosis. Arteriosclec Thromb. Vasc. Biol. (1997) 17:989–995.
   PubMed Web of Science ®Google Scholar
• STEHOUWER CDA, WEIJENBERG MP, VAN DEN BERG M, JAKOBS C, FESKENS EJM, KROMHOUT D: Serum homocysteine and risk of coronary heart disease and cerebrovascular disease in elderly men. A 10-year follow-up. Arteriosclec Thromb. Vasc. Biol. (1998) 18:1895–1901.
   PubMed Web of Science ®Google Scholar
• BOTS ML, LAUNER LJ, LINDEMANS J et al.: Homocysteine and short-term risk of myocardial infarction and stroke in the elderly. Arch. Intern. Med. (1999) 159:38–44.
   PubMed Web of Science ®Google Scholar
• NYGARD O, NORDREHAUG JE, REFSUM H et al: Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl. J. Med. (1997) 337:230–236.
   PubMed Web of Science ®Google Scholar
• OMLAND T, SAMUELSSON A, HARTFORD M et al.: Serum homocysteine concentration as an indicator of survival in patients with acute coronary syndromes. Arch. Intern. Med. (2000) 160:1834–1840.
   PubMed Web of Science ®Google Scholar
• VERHOEF P, HENNEKENS CH, ALLEN RH, STABLER SP, WILLETT WC, STAMPFER MJ: Plasma total homocysteine and risk of angina pectoris with subsequent coronary artery bypass surgery. Am. J. Card. (1997) 79:799–801.
   PubMed Web of Science ®Google Scholar
• PERRY IJ, REFSUM H, MORRIS RW, EBRAHIM SB, UELAND PM, SHAPER AG: Prospective study of serum total homocysteine concentration and risk of stroke in middle-aged British men. Lancet (1995) 346:1395–1398.
   PubMed Web of Science ®Google Scholar
• VERHOEF P, HENNEKENS CH, MALINOW MR, KOK FJ, WILLETT WC, STAMPFER MJ: A prospective study of plasma homocysteine and risk of ischemic stroke. Stroke (1994) 25:1924–1930.
   PubMed Web of Science ®Google Scholar
• PETRI M, ROUBENOFF R, DALLAL GE, NADEAU MR, SELHUB J, ROSENBERG IH: Plasma homocysteine as a risk factor for atherothrombotic events in systemic lupus erythematosus. Lancet (1996) 348(9035):1120–1124.
   PubMed Web of Science ®Google Scholar
• MALINOW MR, KANG SS, TAYLOR LM et al.: Prevalence of hyperhomocysteinemia in patients with peripheral arterial occlusive disease. Circulation (1989) 79:1180–1188.
   PubMed Web of Science ®Google Scholar
• ARONOW WS, AHN C, SCHOENFELD MR: Association between plasma homocysteine and extracranial carotid arterial disease in older persons. Am. J. Cardiol (1997) 79:1432–1433.
   PubMed Web of Science ®Google Scholar
• FERMO I, D'ANGELO SV, PARONI R, MAZZOLA G, CALORI G, D'ANGELO A: Prevalence of moderate hyperhomocysteinemia in patients with early-onset venous and arterial occlusive disease. Ann. Intern. Med. (1995) 123:747–753.
   PubMed Web of Science ®Google Scholar
• MALINOW MR, NIETO FJ, SZKLO M, CHAMBLESS LE, BOND G: Carotid artery intimal-medial wall thickening and plasma homocysteine in asymptomatic adults. Circulation (1993) 87:1107–1113.
   PubMed Web of Science ®Google Scholar
• KONECKY N, MALINOW MR, TUNICK PA et al.: Correlation between plasma homocysteine and aortic sclerosis. Am. Heart J. (1997) 133:534–540.
   PubMedGoogle Scholar
• FONSECA V, GUBA SC, FINK LM: Hyperhomocysteinemia and the endocrine system: implications for atherosclerosis and thrombosis. Endoc. Reviews (1999) 20(5):738–759.
   PubMed Web of Science ®Google Scholar
• TAWAKOL A, OMLAND T, GERHARD M, WU JT, CREAGER MA: Hyperhomocysteinemia is associated with impaired endothelium-dependent vasodilation in humans. Circulation (1997) 95:1119–1121.
   PubMed Web of Science ®Google Scholar
• NAPPO F, DE ROSA N, MARFELLA R et al: Impairment of endothelial functions by acute hyperhomocysteinemia and reversal by antioxidant vitamins. "AMA (1999) 281:2113–2118.
   PubMed Web of Science ®Google Scholar
• SHARMA N, ANDREWS TC: Endothelial function as a therapeutic target in coronary artery disease. Curr: Atherosclei: Reports (2000) 2(4):303–307.
   PubMedGoogle Scholar
• CHASAN-TABER L, SELHUB J, ROSENBERG IH et al.: A prospective study of folate and vitamin B6 and risk of myocardial infarction in US physicians. J. Am. Col. Num. (1996) 15(2):136–143.
   PubMed Web of Science ®Google Scholar
• RIMM EB, WILLETT WC, HU FB et al: Folate and vitamin B6 from diet and supplements in relation to the risk of coronary heart disease among women. "AMA (1998) 279:359–364.
   PubMed Web of Science ®Google Scholar
• WOO KS, CHOOK P, LOLIN YI et aL: Folic acid improves arterial endothelial function in adults with hyperhomocystinemia. I Am. Coll. Cardiol (1999) 34:2002–2006.
   PubMed Web of Science ®Google Scholar
• CHAO CL, CHIEN KL, LEE YT: Effect of short-term vitamin (folic acid, vitamins B6 and B12) administration on endothelial dysfunction induced by post-methionine load hyperhomocysteinemia. Am. .1 Cardiol (1999) 84:1359–1361.
   PubMed Web of Science ®Google Scholar
• CONSTANS J, BLANN AD, RESPLANDY F et al.: Three months supplementation of hyperhomocysteinemic patients with folic acid and vitamin B6 improves biological markers of endothelial dysfunction. Br. J. Haematol (1999) 107:776–778.
   PubMed Web of Science ®Google Scholar
• VAN DEN BERG M, BOERS GHJ, FRANKEN DG et al.: Hyperhomocysteinemia and endothelial cell dysfunction in young patients with peripheral arterial occlusive disease. Eur. Clin. Invest. (1995) 25:176–181.
   Google Scholar
• UNDAS A, DOMAGALA TB, JANKOWSKI M, SZCZEKLIK A: Treatment of hyperhomocysteinemia with folic acid and vitamins B12 and B6 attenuates thrombin generation. Thomb. Res. (1999) 95(6):281–288.
   PubMed Web of Science ®Google Scholar
• DE VECCHI AF, PATROSSO C, NOVEMBRINO C et al: Folate supplementation in peritoneal dialysis patients with normal erythrocyte folate: effect on plasma homocysteine. Nephron (2001) 89(3):297–302.
   PubMed Web of Science ®Google Scholar
• ISHIKAWA M, NAMIKI A, KUBOTA T et al.: Effect of hyperhomocysteinemia on endothelial activation and dysfunction in patients with end-stage renal disease. Am. Cardiol (2001) 88(10):1203–1205.
   PubMed Web of Science ®Google Scholar
• VERMEULEN EGJ, STEHOUWER CDA, TWISK JWR et al.: Effect of homocysteine-lowering treatment with folic acid plus vitamin B6 on progression of subclinical atherosclerosis: a randomized, placebo-controlled trial. Lancet (2000) 355(9203):517–522.
   PubMed Web of Science ®Google Scholar
• MORITA H, KURIHARA H, KUWAKI T et al.: Homocysteine as a risk factor for restenosis after coronary angioplasty. Thromb. Haemost. (2000) 84(1):27–31.
   PubMed Web of Science ®Google Scholar
• KUMBASAR SD, DINCER I, ERTAS F et al.: Hyperhomocysteinemia and restenosis. Cardiovasc. Risk (2001) 8(1):9–13.
   PubMedGoogle Scholar
• SCHNYDER G, ROFFI M, FLAMMER Y, PIN R, HESS OM: Association of plasma homocysteine with restenosis after percutaneous coronary angioplasty. Ear: Heart J. (2002) 23(9):726–733.
   PubMed Web of Science ®Google Scholar
• MINER SE, HEGELE RA, SPARKES J et al.: Homocysteine, lipoprotein (a), and restenosis after percutaneous transluminal coronary angioplasty: a prospective study. Am. Heart J. (2000) 140(2):272–278.
   PubMed Web of Science ®Google Scholar
• GENSER D, PRACHAR H, HAUER R, HALBMAYERW, MLCZOCHJ, IBRAHIM E: Relation of homocysteine, vitamin B12, and folate to coronary in-stent restenosis. Am. J. Card. (2002) 89(5):295–299.
   PubMed Web of Science ®Google Scholar
• SCHNYDER G, MARCO R, PIN R et al: Decreased rate of coronary restenosis after lowering of plasma homocysteine levels. N Engl. J. Med. (2001) 345(22):1593–1600.
   PubMed Web of Science ®Google Scholar
• SCHNYDER G, ROFFI M, FLAMMER Y,PIN R, HESS OM: Effect of homocysteine-lowering therapy with folic acid, vitamin 1312, and vitamin B6 on clinical outcome after percutaneous coronary intervention. The Swiss Heart Study: a randomized controlled trial. JAMA (2002) 288:973–979.
   Google Scholar
• ZHENG H, DIMAYUGA C, HUDAIHED A, KATZ SD: Effect of dexrazoxane on homocysteine-induced endothelial dysfunction in normal subjects. Arterioscler. Thromb. Vase. Biol. (2002) 22:e15–e18.
   Web of Science ®Google Scholar